TRM have been identified as key mediators of allograft rejection (52) and it has been shown in a murine kidney transplant model that treatment with cyclosporine does not prevent CD8+ T cells from acquiring a TRM phenotype (29). This evidence concerns the gene CD8A and medical procedure.